Your session is about to expire
← Back to Search
Sodium-glucose cotransporter 2 (SGLT2) inhibitor
Canagliflozin for Heart Disease (CANTORSING Trial)
Phase 2 & 3
Recruiting
Led By Kevin Boczar, MD
Research Sponsored by Ottawa Heart Institute Research Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Stable CAD (over 60 days post-myocardial infarction)
Be older than 18 years old
Must not have
Active infection (e.g. pneumonia, active skin infections, and on antibiotics)
Unable to give informed consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
All Individual Drugs Already Approved
Summary
This trial is a small study to see if a medication called canagliflozin can reduce inflammation in the arteries of patients with heart disease. They will compare the effects of canaglif
Who is the study for?
This trial is for people who have stable coronary artery disease (CAD) at least 60 days after a heart attack and also have type 2 diabetes. Participants must be willing to give informed consent.
What is being tested?
The study compares Canagliflozin, a medication given daily, with a placebo over six months to see if it reduces inflammation in the blood vessels of patients with CAD and diabetes.
What are the potential side effects?
Canagliflozin may cause side effects like yeast infections, urination issues, and possibly an increased risk of bone fractures or lower limb amputations.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I had a heart attack over 2 months ago and my heart condition has been stable since.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I currently have an active infection and am taking antibiotics.
Select...
I am unable to understand and give consent for treatment.
Select...
My heart's pumping ability is significantly reduced.
Select...
I agree to use two forms of contraception if I can have children.
Select...
My kidney function is reduced with a GFR less than 50.
Select...
I am not taking medications like cyclosporine, verapamil, or ketoconazole.
Select...
I have severe heart failure that is not well-controlled.
Select...
I have an active inflammatory condition or am on systemic anti-inflammatory therapy.
Select...
I have severe liver disease or my ALT levels are three times above the normal limit.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
TBR (Tissue-to-blood ratio) of the most-diseased segment (MDS) of the ascending aorta
Secondary study objectives
Change in inflammatory biomarkers
Change in monocyte marker expression
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: ActiveActive Control1 Intervention
Canagliflozin 300mg PO daily
Group II: PlaceboPlacebo Group1 Intervention
Placebo PO daily
Find a Location
Who is running the clinical trial?
Ottawa Heart Institute Research CorporationLead Sponsor
196 Previous Clinical Trials
93,673 Total Patients Enrolled
50 Trials studying Coronary Artery Disease
37,837 Patients Enrolled for Coronary Artery Disease
Kevin Boczar, MDPrincipal InvestigatorOttawa Heart Institute Research Corporation
1 Previous Clinical Trials
115 Total Patients Enrolled
Gary Small, MD, PhDPrincipal InvestigatorOttawa Heart Institute Research Corporation